Skip to main navigation Skip to search Skip to main content

Three-Year Outcomes with the Absorb Bioresorbable Scaffold

  • Ziad A. Ali
  • , Runlin Gao
  • , Takeshi Kimura
  • , Yoshinobu Onuma
  • , Dean J. Kereiakes
  • , Stephen G. Ellis
  • , Bernard Chevalier
  • , Minh Thien Vu
  • , Zhen Zhang
  • , Charles A. Simonton
  • , Patrick W. Serruys
  • , Gregg W. Stone
  • Columbia University Medical Center
  • Cardiovascular Research Foundation
  • Chinese Academy of Medical Sciences
  • Kyoto University Hospital
  • Erasmus MC
  • Lindner Research Center
  • Cleveland Clinic Foundation
  • Hôpital Privé Jacques Cartier
  • Abbott Vascular
  • Imperial College London

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

190 Citations (Scopus)

Abstract

Background: The Absorb bioresorbable vascular scaffold (BVS) completely resorbs within 3 years after coronary artery implantation. The safety and effectiveness of BVS through this critical 3-year period have not been characterized. Methods: We performed an individual-patient-data pooled meta-analysis of the 4 randomized ABSORB trials in which 3389 patients with coronary artery disease were randomly assigned to everolimus-eluting Absorb BVS (n=2164) or cobalt-chromium everolimus-eluting stents (n=1225). The primary efficacy outcome measure was target lesion failure (cardiac mortality, target vessel myocardial infarction, or ischemia-driven target lesion revascularization), and the primary safety outcome measure was device thrombosis. Results: BVS compared with cobalt-chromium everolimus-eluting stents resulted in higher 3-year rates of target lesion failure (11.7% versus 8.1%; risk ratio [RR], 1.38; 95% confidence interval [CI], 1.10-1.73; P=0.006), driven by greater target vessel myocardial infarction (7.8% versus 4.2%; RR, 1.72; 95% CI, 1.26-2.35; P=0.0006) and ischemia-driven target lesion revascularization (6.6% versus 4.4%; RR, 1.44; 95% CI, 1.05-1.98; P=0.02), with comparable cardiac mortality (1.1% versus 1.1%; RR, 0.93; 95% CI, 0.47-1.88; P=0.85). Device thrombosis rates through 3 years were also higher with BVS (2.4% versus 0.6%; RR, 3.71; 95% CI, 1.70-8.11; P=0.001). Between 1 and 3 years, target lesion failure rates (6.1% versus 3.9%; P=0.02) and device thrombosis rates (1.1% versus 0.0%; P<0.0001) were higher with BVS than cobalt-chromium everolimus-eluting stents. Conclusions: In the present individual-patient-data pooled meta-analysis of the ABSORB trials, BVS was associated with increased rates of target lesion failure and device thrombosis between 1 and 3 years and cumulatively through 3 years of follow-up compared with everolimus-eluting stents. Clinical Trial Registration: URL: https://clinicaltrials.gov. Unique identifiers: NCT01751906, NCT01844284, NCT01923740, and NCT01425281.

Original languageEnglish
Pages (from-to)464-479
Number of pages16
JournalCirculation
Volume137
Issue number5
DOIs
Publication statusPublished - 30 Jan 2018
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • coronary artery disease
  • drug-eluting stents
  • meta-analysis [publication type]
  • percutaneous coronary intervention
  • stents

Fingerprint

Dive into the research topics of 'Three-Year Outcomes with the Absorb Bioresorbable Scaffold'. Together they form a unique fingerprint.

Cite this